Supplementary Table 2. Summary of TEAEs/AESIs and incidence of AESIs by system organ class and preferred term

Variable	Placebo (n=141)	Evogliptin (n=141)	P value
Subjects with TEAEs			
24 weeks	32 (22.70) [48]	39 (27.66) [61]	0.4105
52 weeks	48 (34.04) [80]	50 (35.46) [101]	0.9005
Subjects with AESIs			
24 weeks	3 (2.13) [4]	4 (2.84) [5]	1.0000
52 weeks	4 (2.84) [5]	4 (2.84) [6]	1.0000
Musculoskeletal and connective tissue disorders	3 (2.13) [3]	1 (0.71) [2]	
Arthralgia	3 (2.13) [3]	1 (0.71) [2]	
Investigations	1 (0.71) [1]	2 (1.42) [3]	
Lipase increased	1 (0.71) [1]	1 (0.71) [2]	
Lipase abnormal	0 [0]	1 (0.71) [1]	
Metabolism and nutrition disorders	1 (0.71) [1]	1 (0.71) [1]	
Hypoglycemia	1 (0.71) [1]	1 (0.71) [1]	

Values are presented as number of subject (percentage of subject) [number of event]. Difference between treatment groups was analyzed using the Fisher's exact test.
TEAE, treatment-emergent adverse event; AESI, adverse event of special interest.